Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662597 · ClinicalTrials.gov registry record · Phase 3
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,285
- Enrollment target
NCT00662597 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 1,285 participants.
The verdict
NCT00662597, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,285 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Interventions
- DRUG Placebo
- DRUG Paclitaxel
- DRUG carboplatin
- DRUG ASA404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,285 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662597
The ClinicalTrials.gov registry entry for NCT00662597 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00662597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662597 about?
NCT00662597 is a clinical study titled "ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer". The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
What is the current status of trial NCT00662597?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,285 participants. The study started on 2008-04. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00662597?
The interventions under investigation include: Placebo (DRUG), Paclitaxel (DRUG), carboplatin (DRUG), ASA404 (DRUG).
Who is sponsoring clinical trial NCT00662597?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.